BCL2 and hepatocellular carcinoma: Baohuoside-1 inactivates the mTOR signaling pathway in hepatocellular carcinoma (HCC) in a dose-dependent manner, reduces Bcl-2 expression, and enhances cleaved caspase3 and Bax expression (Guo et al., 2020).